Comparison of different lateral flow assays on bronchoalveolar lavage fluid for invasive aspergillosis screening in non-hematological patients

• Published in: Journal de mycologie médicale 2024-06, Vol.34 (2), p.101481, Article 101481
• Main Authors: Devillers, Eliane, Scherer, Emeline, Navellou, Jean-Chistophe, Grenouillet, Frédéric, Millon, Laurence, Bellanger, Anne-Pauline
• Format: Article
• Language: English
• Subjects: Fungal diagnostics; Galactomannan; Invasive aspergillosis screening; Lateral flow assay; Opportunistic infections
• ISSN: 1156-5233; 1773-0449; 1773-0449
• DOI: 10.1016/j.mycmed.2024.101481

Several lateral flow assays (LFA) capable of detecting Aspergillus fumigatus in serum and broncho-alveolar lavage fluid (BALF) within the hour, thereby potentially accelerating the screening process, are now commercially available. We prospectively compared three LFA targeting A. fumigatus on BALF collected from non-surgical intensive care patients between June 2022 and February 2023. The three LFA tested were Sõna Aspergillus galactomannan LFA (Immy), Fungadia Aspergillus antigen (Gadia), and AspLFD (OLM Diagnostics). We compared the results of these LFA with those of the galactomannan (GM) Platelia Aspergillus enzyme immunoassay (Bio-Rad), culture on Sabouraud medium and Aspergillus qPCR. We tested 97 BALF samples from 92 patients. In total 84 BALF samples tested negative with all three LFA, and four BALF samples tested positive with the AspLFD assay only (OLM). Only one BALF sample tested positive with the three LFA. In addition, three BALF samples tested positive only with the GM Platelia immunoassay. Four diagnosis of probable invasive aspergillosis were retained for the 92 patients tested. This prospective series included very few positive samples. From a practical point of view, the LFA from OLM presented the simplest protocol for use.